Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & Administrative
Others
Ratios

Cogent Biosciences (COGT) EBITDA (2017 - 2021)

Cogent Biosciences has reported EBITDA over the past 5 years, most recently at -$24.9 million for Q4 2021.

  • Quarterly results put EBITDA at -$24.9 million for Q4 2021, down 119.72% from a year ago — trailing twelve months through Dec 2021 was -$72.2 million (up 3.43% YoY), and the annual figure for FY2025 was -$329.0 million, down 28.7%.
  • EBITDA for Q4 2021 was -$24.9 million at Cogent Biosciences, down from -$19.1 million in the prior quarter.
  • Over the last five years, EBITDA for COGT hit a ceiling of $2.3 million in Q4 2019 and a floor of -$50.0 million in Q3 2020.
  • Median EBITDA over the past 5 years was -$9.6 million (2018), compared with a mean of -$11.9 million.
  • Biggest five-year swings in EBITDA: surged 126.73% in 2019 and later crashed 593.6% in 2020.
  • Cogent Biosciences' EBITDA stood at -$6.7 million in 2017, then fell by 28.61% to -$8.6 million in 2018, then skyrocketed by 126.73% to $2.3 million in 2019, then crashed by 593.6% to -$11.3 million in 2020, then plummeted by 119.72% to -$24.9 million in 2021.
  • The last three reported values for EBITDA were -$24.9 million (Q4 2021), -$19.1 million (Q3 2021), and -$16.5 million (Q2 2021) per Business Quant data.